CD38 and acute myeloid leukemia: With this limitation, clinical studies focused on CD33, CD123, and CD371 (CLL-1/Cec12), which show sufficient differential expression on AML and hematopoietic cells, and other potential targets, such as CD38, FLT3, CD56, CD30, CD7, and CD25, are under investigation (Figure 3).